Freenome Reports Data for Multiomic Blood-Based Screening Test for Lung Cancer

The data, generated from a study designed to optimize ongoing test refinement, will be presented at the AACR Annual Meeting in April

Excerpt from the Press Release:

BRISBANE, Calif., March 18, 2026 /PRNewswire/ — Freenome, an early cancer detection company developing blood-based screening tests, today announced initial development data for its investigational lung cancer screening test. The data demonstrate the potential of a multiomics approach that combines DNA methylation analysis and protein markers to detect lung cancer in high-risk individuals.

Freenome investigators will present the data at next month’s AACR Annual Meeting in San Diego. Poster presentation details:

• Abstract Number: 1107
• Title: Development and performance of a multiomics lung cancer screening blood test
• Presenter: Ofer Shapira, Freenome director of computational biology
• Session Title: Early Detection Biomarkers 1
• Session Date and Time: Sunday, April 19, 2:00 PM – 5:00 PM PDT

For the study, an AI/ML classifier was trained on tissue (n=136) and plasma (n=6,716) samples. The test’s accuracy was evaluated in 673 plasma samples, including 363 lung cancer cases across all stages and 310 cancer-negative controls, from individuals matching the intended screening population (adults aged 50-80 with high-risk smoking history).

In this cohort, Freenome’s proprietary multiomics platform — using base-resolution methylation sequencing of circulating cell-free DNA (cfDNA) and plasma protein immunoassays — achieved adjusted sensitivity* of 90.7% at 50% specificity and 80.4% at 75% specificity for detecting lung cancer. The multiomic approach outperformed a methylation-only version of the test, which showed adjusted sensitivities of 85.8% and 78.2% at the same specificity thresholds.

Click the button below to read the entire Press Release:

Continue Reading The Press Release